Collegium Pharmaceutical (NASDAQ:COLL) Price Target Lowered to $36.00 at Piper Sandler

Collegium Pharmaceutical (NASDAQ:COLL) had its target price cut by Piper Sandler from $37.00 to $36.00 in a research note released on Tuesday,Benzinga reports. They currently have a neutral rating on the specialty pharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock opened at $30.93 on Tuesday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company’s 50-day moving average price is $31.03 and its two-hundred day moving average price is $34.16. Collegium Pharmaceutical has a 52 week low of $28.39 and a 52 week high of $42.29. The stock has a market cap of $997.49 million, a PE ratio of 13.33 and a beta of 0.82.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.98% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Large investors have recently made changes to their positions in the business. GAMMA Investing LLC grew its stake in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares in the last quarter. CWM LLC grew its stake in shares of Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares in the last quarter. TD Private Client Wealth LLC grew its stake in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares in the last quarter. Virtus Fund Advisers LLC bought a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $72,000. Finally, KBC Group NV grew its stake in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.